Conmed (CNMD) Equity Average (2011 - 2026)

Conmed has reported Equity Average for 16 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 5.69% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 5.69% YoY), and the FY2025 full-year result was $997.9 million, up 11.07% from the prior year.
• Equity Average for Q1 2026 stood at $1.0 billion, roughly flat from $1.0 billion in the prior quarter.
• The five-year high for Equity Average was $1.0 billion in Q1 2026, with the low at $694.7 million in Q3 2022.
• Historically, Equity Average has averaged $861.4 million across 5 years, with a median of $844.4 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average slipped 7.39% — and 2024, when it advanced 16.26%.
• Conmed's Equity Average stood at $730.9 million in 2022, then rose by 11.53% to $815.2 million in 2023, then gained by 16.26% to $947.8 million in 2024, then advanced by 7.69% to $1.0 billion in 2025, then grew by 0.46% to $1.0 billion in 2026.
• The last three Equity Average figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.